RxDoctor Payments Data

Logan Vincent, MD

Interventional Cardiology · Portland, ORNPI 1164764288

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $27,825 of the $42,310 with a category attached, or 65.8%. Edwards Lifesciences accounts for 82.6% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $20,913, more than ten times the $121 reported in 2019.

$42,310in general payments, 2019–2025

Across 149 payments — averaging $283.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$35K
  • Abbott$3K
  • Medtronic$3K
  • Ancora Heart, Inc.$675
  • Boston Scientific$226
  • Impulse Dynamics (USA) Inc.$125
  • plus $167 from 3 others
$64,075in research payments, 2019–2025

Across 31 payments — averaging $2066.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$53K
  • Abbott$11K

What the payments were for

  • Consulting fees$27,82566%
  • Travel & lodging$8,35220%
  • Food & beverage$6,13214%
  • Education$10%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Edwards Lifesciences73$34,966
Abbott34$3,218
Medtronic31$2,933
Ancora Heart, Inc.5$675
Boston Scientific2$226
Impulse Dynamics (USA) Inc.1$125
Philips North America LLC1$121
Teleflex LLC1$26
Cardiac Dimensions, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,310 in reported general payments places this provider in the 85th percentile of 68 interventional cardiology providers in Oregon.

See all interventional cardiology providers in Oregon

Medicare billing

Part B allowed, 2024
$120,319
Medicare patients
193
Services billed
387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$11,185
Atorvastatin Calcium25$268
ClopidogrelClopidogrel Bisulfate28$233
Metoprolol Succinate16$190

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →